Literature DB >> 12010992

The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin.

A-S Beignon1, J-P Briand, R Rappuoli, S Muller, C D Partidos.   

Abstract

Application of antigens with an adjuvant onto bare skin is a needle-free and pain-free immunization procedure that delivers antigens to the immunocompetent cells of the epidermis. We tested here the immunogenicity and adjuvanticity of two mutants of heat-labile enterotoxin (LT) of Escherichia coli, LTK63 and LTR72. Both mutants were shown to be immunogenic, inducing serum and mucosal antibody responses. The application of LTK63 and LTR72 to bare skin induced significant protection against intraperitoneal challenge with a lethal dose of LT. In addition, both LT mutants enhanced the capacity of peptides TT:830-843 and HA:307-319 (representing T-helper epitopes from tetanus toxin and influenza virus hemagglutinin, respectively) to elicit antigen-specific CD4(+) T cells after coapplication onto bare skin. However, only mutant LTR72 was capable of stimulating the secretion of high levels of gamma interferon. These findings demonstrate that successful skin immunization protocols require the selection of the right adjuvant in order to induce the appropriate type of antigen-specific immune responses in a selective and reliable way. Moreover, the use of adjuvants such the LTK63 and LTR72 mutants, with no or low residual toxicity, holds a lot of promise for the future application of vaccines to the bare skin of humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010992      PMCID: PMC128003          DOI: 10.1128/IAI.70.6.3012-3019.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines.

Authors:  M Sakaguchi; S Inouye
Journal:  Vaccine       Date:  2000-04-03       Impact factor: 3.641

2.  Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines.

Authors:  G B Lipford; T Sparwasser; M Bauer; S Zimmermann; E S Koch; K Heeg; H Wagner
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

3.  Delineation of several DR-restricted tetanus toxin T cell epitopes.

Authors:  S Demotz; A Lanzavecchia; U Eisel; H Niemann; C Widmann; G Corradin
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

Review 5.  The skin immune system: progress in cutaneous biology.

Authors:  J D Bos; M L Kapsenberg
Journal:  Immunol Today       Date:  1993-02

6.  CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).

Authors:  Monica M McNeal; John L VanCott; Anthony H C Choi; Matili Basu; Jason A Flint; Susan C Stone; John D Clements; Richard L Ward
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.

Authors:  E J Ryan; E McNeela; G A Murphy; H Stewart; D O'hagan; M Pizza; R Rappuoli; K H Mills
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

8.  Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin.

Authors:  J J Guidry; L Cárdenas; E Cheng; J D Clements
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

9.  Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity.

Authors:  M M Giuliani; G Del Giudice; V Giannelli; G Dougan; G Douce; R Rappuoli; M Pizza
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

10.  Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity.

Authors:  S Yamamoto; Y Takeda; M Yamamoto; H Kurazono; K Imaoka; M Yamamoto; K Fujihashi; M Noda; H Kiyono; J R McGhee
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

View more
  8 in total

1.  Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice.

Authors:  Tsuyoshi Itoh; Esteban Celis
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

Review 2.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

3.  Immunological activation following transcutaneous delivery of HR-gp100 protein.

Authors:  Shoshana Frankenburg; Igor Grinberg; Ziva Bazak; Lena Fingerut; Jacob Pitcovski; Raphael Gorodetsky; Tamar Peretz; Ram M Spira; Yehuda Skornik; Ronald S Goldstein
Journal:  Vaccine       Date:  2007-04-25       Impact factor: 3.641

4.  Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Authors:  Paul Stickings; Marisa Peyre; Laura Coombes; Sylviane Muller; Rino Rappuoli; Giuseppe Del Giudice; Charalambos D Partidos; Dorothea Sesardic
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

5.  Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations.

Authors:  Michael Vajdy; Manmohan Singh; Mildred Ugozzoli; Maylene Briones; Elawati Soenawan; Lina Cuadra; Jina Kazzaz; Paolo Ruggiero; Samuele Peppoloni; Francesco Norelli; Giuseppe del Giudice; Derek O'Hagan
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

6.  GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation.

Authors:  Qingfeng Chen; Fang He; Jimmy Kwang; Jerry K Y Chan; Jianzhu Chen
Journal:  J Immunol       Date:  2012-10-22       Impact factor: 5.422

Review 7.  Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.

Authors:  Frank R Brennan; Leigh Shaw; Mark G Wing; Christine Robinson
Journal:  Mol Biotechnol       Date:  2004-05       Impact factor: 2.860

Review 8.  Hib Vaccines: Past, Present, and Future Perspectives.

Authors:  Adi Essam Zarei; Hussein A Almehdar; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-01-20       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.